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Introduction 
Vibrio cholerae is a noninvasive enteric pathogen and is responsible for cholera, a disease notable for 
severe diarrhea, rapid dehydration, and sometimes death if not adequately treated. Even though almost 
150 years have passed since this pathogen and its major routes of transmission were documented (Koch 
1884), cholera continues to exert a considerable burden in both endemic and epidemic settings. 
Humans are the only known reservoir of Vibrio cholera, with a long and complex interaction between 
the pathogen and its host. Cholera has had a profound and sustained influence on human genetics and 
behavior. The enormous dread of cholera catalyzed the development of sanitation in 1800’s, 
intravenous fluids, oral rehydration therapy, quarantines and further understanding of physiology and 
disease transmission  that has reduced mortality not only of cholera but of many human diseases. 
Despite this progress, estimates suggest 2.8 million cases and 91,000 deaths due to cholera per year in 
endemic countries (Ali 2012).  
Cholera was successfully eliminated from the Western Hemisphere in the 1887 through a combination 
of aggressive quarantine of incoming ships and sanitation improvement. Unfortunately, cholera was 
reintroduced in Peru in 1991 (Guerrant 2003). The bacteria inexorably marched back through previously 
cleared areas. A combination of denser populations, greater ease of transport, and weaker centralized 
power made duplicating the success of the previous century impossible. In Trujillo, Peru the attack rate 
in two months in 1991 was 2.6%. Due to contamination of the water supply and irrigation of produce 
field with sewage contaminated water, a large proportion of the population was exposed. A swift 
response of a public health system with adequate resources, as well as a knowledge of oral rehydration 
solution in the general population kept the case fatality rate at .04% (Swerdlow 1992). By contrast, in 
Haiti not only was the attack rate higher at 3.8%, but the case fatality rate was 1.4% (CDC 2012). The 
difference stems from weaker infrastructure or a more susceptible population, either from malnutrition 
or coinfections.  
Epidemics such as the outbreak in Haiti demonstrate that delays in implementing the standard 
interventions of treatment centers, fluid support, and antibiotics can cost many lives (JAMA 2011). 
Additionally, the emergence of antibiotic resistant strains will continue to complicate case management 
(Faruque 2006). Unfortunately, both endemic and epidemic cholera continue to affect communities with 
challenges implementing cholera preventive or therapeutic measures. In such situations, an effective 
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cholera vaccine administered as a part of routine childhood immunizations or an immunization 
campaign could cheaply and effectively reduce the burden of cholera. A vaccine could theoretically 
protect from disease either by an antibacterial response preventing the replication of the bacteria 
within the small intestine or by an antitoxic response neutralizing the toxin without necessarily 
preventing replication of the bacteria. Cholera toxin is A-B heat labile enterotoxin, closely related to the 
labile toxin found in some strains of E. coli that also cause massive watery diarrhea. Five B subunits bind 
the ganglioside GM1 receptor on the surface of enterocytes and form a pore in the membrane of the 
enterocyte. The A protein enters the pore and activates intracellular adenylyl cyclase. The resulting 
increased level of cAMP stimulate the efflux of chloride ions through the CFTR channel. Water follows 
osmotically, resulting in large fluid losses (Mekalanos 1983). 
Although an antitoxic response would be very effective at reducing morbidity and mortality in those 
vaccinate by interfering with the process outlined above, the advantage of an antibacterial response is 
that the person vaccinated is not only protected from clinical disease but also prevented from exposing 
others to a potentially deadly pathogen. Developing an effective cholera vaccine should be achievable 
because natural infection induces a sustained antibacterial and antitoxin response. Volunteers 
experimentally infected with cholera then challenged after three years showed complete protection 
against disease, which affected 4/5 naïve controls, and 3/4 previously infected volunteers did not shed 
any bacteria in their stool whereas all naïve volunteers shed bacteria in their stool (Levine 1981). 
Koch recognized that individuals who recovered from cholera were protected from further disease in 
the same outbreak, but that they remained susceptible to outbreaks occurring in subsequent years. He 
used the acquirement of immunity to explain why cholera outbreaks resolved in places outside of India 
(Koch 1884). In endemic settings, much of the population carries a degree of immunity from past 
infection or exposure, and children bear the burden of severe disease and death. Although the 
protective efficacy of natural infection is the same in cases younger or older than 5 years (Ali 2011), 
current oral killed vaccines have demonstrated decreased efficacy and duration of protection in younger 
children.  In particular, children have a decreased cellular (Leung 2012) and antibody (Leung 2013) 
response to vaccination, whereas this deficit is not seen in natural infection (Arifuzzaman 2012). 
The major pathogenic serogroups of V. cholerae, O1 and O139, and major O1 serotypes, Inaba and 
Ogawa are defined by the arrangement of sugars in the O-specific polysaccharide (OSP) moiety in the 
membrane lipopolysaccharide LPS. Natural infection with V. cholerae Inaba induces protective immunity 
to reinfection with either Inaba or Ogawa strains, whereas infection with Ogawa protects against 
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reinfection with Ogawa but less well against Inaba (Ali 2011). The dominant serotype can shift as a 
critical proportion of the population develops protective immune responses against the endemic strains. 
Experimental infection in immunologically naïve volunteers also shows profound and sustained 
protection that lasts at least three years after initial infection (Levine 1981) and to 6-10 years in 
epidemiologic studies (Koelle 2005). Currently available oral killed cholera vaccines have declining 
efficacy after 6-60 months (WHO 2010). Two licensed cholera vaccines, Dukoral and Shanchol, are 
currently in use, and more have been used in the past or started down the path of development (Shin 
2011). No cholera vaccine, however, has demonstrated protective efficacy equivalent to that of natural 
exposure. Both Dukoral and Shanchol oral killed vaccines given in two doses and recommended oral 
booster every two years (WHO 2010)(Shin 2011). Dukoral has been shown to produce an overall 
memory B-cell response of lower magnitude and duration than natural cholera infection. Intriguingly, 
oral killed vaccines do not reproduce the robust memory B cell response to serospecific LPS observed to 
correlate with long-term protection following natural infection (Harris 2009). The memory response to 
cholera toxin and OSP is correlated with the affinity of the antibodies stimulated in the initial exposure 
(Alam 2013).  
 Specific mutants of LPS show that the OSP moiety is necessary and sufficient for the full passive immune 
effect of antibodies raised against LPS (Leitner 2013). The fact that there is no cross protection between 
serogroups of V. cholerae (Ali 2011) provides further evidence that immunologic response to the 
appropriate OSP moiety is necessary for protection. Since the Lipid A portion is responsible for the toxic 
effects of LPS, a vaccine composed of just the OSP could provide the beneficial effects without the 
toxicity. LPS preparations can also show a great variety in composition depending upon the 
manufacturing process (Johnson 2012). Any commercial vaccine preparation would require a pure and 
replicable preparation process. 
OSP is entirely polysaccharide chains, which do not stimulate a robust immune response, especially 
among young children (Peltola 1984). Previous vaccines linking Inaba OSP to a protein have been tested 
in humans (Gupta 1998). Although multiple methods exist to conjugate protein to the OSP, the 
conjugation can alter the OSP structure, impeding immunogenicity (Xu 2011). A novel method to 
conjugate OSP to protein to increase immunogenicity without affecting the hapten structure was 
previously described (Xu 2011). Aluminum adjuvants enhance antibody response to vaccines and are 
widely used in currently licensed vaccines (HogenEsch 2002). Aluminum adjuvants have been specifically 
observed to increase the IgG response to conjugate polysaccharide vaccines (Wuorimaa 2001). Here, we 
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report characterization of an Inaba OSP cholera conjugate vaccine in mice administered with and 
without an aluminum adjuvant, with the aim to answer whether the OSP Inaba conjugate vaccine is 
immunogenic in mice and whether the addition of alum enhances the antibody response.  
Methods:  
We isolated Inaba LPS from solid colonies of Vibrio cholera O1 Inaba El Tor strain PIC018, a clinical 
isolate recovered in Bangladesh, via hot phenol extraction as previously described (Westfal 1965). The 
isolate was treated with enzymes (nuclease and protease), dialyzed against water and processed as has 
been previously decribed (Xu 2011). Briefly, we hydrolyzed the LPS with acetic acid to form OSP, which 
we extracted with equal volumes of chloroform, pelleted with ultracentrifugation, then lyophilized. We 
conjugated the OSP to BSA or a recombinant fragment of tetanus toxoid heavy chain (rTTHc), as 
previously described (Xu 2011, Alam 2014). To enhance purity, we introduced additional filtration steps 
of OSP to remove any product smaller than 3kDa, or larger than 30 kDa prior to use in conjugation. 
Female Swiss-Webster mice three to five weeks old were intramuscularly vaccinated on days 0, 14, and 
28 in cohorts of ten to fifteen mice. The vaccine was composed of Inaba OSP conjugated to rTTHc at a 
5:1 molar ratio of OSP to rTThc. Each injection consisted of 10 ug of OSP. In one group of mice, the 
vaccine was mixed in a 1:1 v/v ratio with Alum and delivered in a single injection. Control mice were 
vaccinated with Alum alone. We tail bled the mice on days 0, 7, 14, 28, 35, and 42. We centrifuged the 
blood at 5K g for ten minutes to isolate the serum, which we removed and stored at -80°C until 
processing.  
Elisa:  
We coated 96 well plates overnight at room temperature with either Inaba LPS (2.5 µg/mL in PBS, 100ul 
per well) or OSP-BSA. After a wash with PBS, we blocked the plates with 200 µl/ well 1% bovine serum 
albumin in phosphate buffered serum for forty minutes at 37°C to reduce non-specific protein binding. 
We diluted the serum 1:25 in 0.1% BSA-PBS-Tween (0.05%) and incubated the ELISA plate for ninety 
minutes at 37°C. After washing the plates three times with PBS-Tween .05%,  we added 100 µl /well 
horseradish peroxidase conjugated goat anti-mouse IgG and IgM (Southern Biotechnology); 1:1000 
dilution in .1% BSA-PBS-Tween (0.05%) and incubated for ninety minutes at 37°C. The plates were 
washed three times with PBS-Tween and once with PBS and read kinetically for five minutes at thirty 
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second intervals at an optical density at 405nm after the addition of 100 µl per well of µl 12 µl 30%H2O2 
in 12 mL ABTS. The maximum slope for an optical density change of 0.2U was termed the millioptical 
density units per minute (Alam 2014). Elisa units (EU) were calculated as the ratio to control pooled 
serum from mice in prior experiments.  
Vibriocidal: 
The vibriocidal assay has long been observed to be a correlate of protection against cholera, and has 
been characterized to largely correlate with IgM levels against LPS and OSP (Johnson 2012). We grew 
the vaccine strain of Inaba V. cholera O1 PIC018 overnight in 5 ml liquid culture (5ml LB with 5 µl 
streptomycin). We made 4 1-mL aliquots of the liquid culture and spun at 5000 rotations per minute for 
ten minutes. We resuspended the pellet in 1 ml of 0.15 M saline and diluted to a standard concentration 
of 0.1 OD at 600nm. We heated 13µl serum for one hour at 56° C to inactivate the endogenous mouse 
complement. The serum was diluted 1:25 by adding 312 µl sterile saline to the 13 µl heat inactivated 
serum. Then we serially diluted the serum solution in duplicate at a 1:2 concentration. We added 39 µl 
of the bacterial suspension and 11 µl Guinea Pig Complement (Gibco BRL) to each well of the serially 
diluted serum samples and incubated sixty minutes at 37°C on a rocker for mild agitation. We added 150 
µl of brain heart infusion media to all wells and incubated at 37°C until the control wells without any 
complement were between 0.2 and 0.3 OD. We counted the vibriocidal response as the reciprocal of the  
highest dilution at which the OD of the well was less than half that of the control wells without serum.  
Protection: 
As previously described, we mixed wild type V. cholera with pooled serum from adult immunized mice 
(Alam 2014). In the challenge, we used cohorts of 20 3-5 day old unimmunized CD1 suckling mice. The 
pups were separated from their mothers for three hours, then we introduced 50 µl of the mixture of 
bacteria and serum via a tube into the stomachs of infant mice. Deaths during the first 12 hours were 
considered to be related to the procedure rather than the bacteria. After the first 12 hours, the survival 
of the infant mice were counted every three hours. Animals surviving past 36 hours were euthanized.  
Statistics and Graphs: 
Groups were compared to each other using the Mann-Whitney U test. Within each group, we assessed 
the change from baseline using Wilcoxon Signed-Rank tests. We used Kaplan-Meyer survival analysis to 
look at the protection in mouse pups. Statistical significance was based on two-tailed p-value less than 
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0.05. Graphs and calculations were produced using the GraphPad Prism 4 (GraphPad Software, Inc., La 
Jolla, CA). 
Results 
ELISA: By day 21, mice vaccinated with the conjugate vaccine developed a significant IgG response to 
OSP, whether or not adjuvant was used (Figure 1). The antibody response remained significantly 
elevated above baseline for the duration of the experiment. Mice vaccinated with the vaccine and 
adjuvant produced a significant IgG response to LPS by day 14, and mice vaccinated without the 
adjuvant produced a significant IgG response to LPS by day 35. Mice who received the vaccine with 
adjuvant did not produce a significant IgM response to either LPS or OSP. Mice receiving the vaccine 
alone produced a significant IgM response to OSP by day 14 and IgM response to LPS by day 21. 
Vibriocidal: Both the mice vaccinated with the vaccine as well as the vaccine with Alum adjuvant 
produced a statistically significant increase in vibriocidal titer from baseline (Figure 2). Mice immunized 
with adjuvant alone did not produce a significant vibriocidal response.  
Protection: The serum from mice vaccinated with the vaccine with Alum as an adjuvant demonstrated 
statistically significant protection compared with serum from mice vaccinated with Alum alone (Figure 
3). Of the mice pups treated with serum from vaccinated mice, 10/17 (58.8%) survived to 36 hours 
compared with 1/13 (7.7%)( p=.0006) of mice who received serum from mice vaccinated with Alum 
alone. 
Discussion 
We demonstrated that a novel Inaba cholera conjugate vaccine induces a robust serologic response that 
inhibited growth of V. cholerae in vitro and also provided protection in the neonatal mouse challenge 
model. Notably, the addition of Alum as an adjuvant did not significantly improve response.  
 
This vaccine consists of an OSP :rTThc conjugate. OSP alone is a T-cell independent antigen. Conjugating 
the carbohydrate OSP to a protein, even a protein not naturally encountered in conjunction with the 
carbohydrate, makes the conjugate accessible to the T-cell dependent pathway. The protein portion of 
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the conjugate can be displayed on antigen-presenting cells via MHC Class II molecules, particularly in 
germinal centers, where antigen-presenting cells interact with T-cells and B-cells. T-cells activated by the 
peptide-MHC are able to stimulate the B-cells that recognize the carbohydrate moiety not only to 
undergo affinity maturation and class switching but also to develop a subset of memory B-cells (Clarke 
2013). Memory B-cells account for the ability to mount a rapid and specific antibody response to 
pathogens even decades after the initial exposure. Immunity generated by T-cell independent antigens 
wanes much more quickly, likely reflecting the shorter lifespan of plasma cells compared to memory B-
cells. Adults with mature immune systems and primed B-cells are capable of mounting a boosted 
response to T-cell independent antigens. Children, particularly those less than two years of age, have a 
limited ability to mount an immune response to T-cell independent antigens (Clarke 2013). The failure of 
current oral killed vaccines to stimulate a memory B-cell response or maintain protection equivalent to 
natural infection (Harris 2009), along with the impaired protection in young children suggests that the 
current vaccines are not stimulating T-cell dependent immunity. Indeed, a memory T-cell response to 
cholera toxin in people of all ages receiving the oral cholera vaccine has been seen to predict later 
memory B cell responses to the same antigen. Though even young children are able to mount a memory 
T-cell response to natural cholera infection, they show impaired memory T-cell responses to oral cholera 
vaccines (Arifuzzaman 2012). 
Tetanus toxoid presents an attractive conjugate protein, being safe and highly immunogenic in humans. 
Tetanus toxoid conjugate vaccines have FDA approval and are currently in commercial use. The use of 
tetanus toxoid in one version of the Haemophilus influenzae b conjugate vaccine illustrates the power of 
protein conjugation when targeting a polysaccharide from a pathogen with a large mortality and 
morbidity in infants and young children. Since evidence suggests that immune responses to subsequent 
reexposure to a polysaccharide in the absence of a stimulating peptide can be reduced over time (Clarke 
2013), conjugating OSP to a protein might stimulate a memory response that can be strongly boosted 
upon exposure to natural infection or revaccination.  
Cholera is an enteric pathogen and exposure and protection are mediated though interactions in the 
enteric mucosa. Further work is needed to assess the effect of this vaccine on protection at mucosal 
surfaces. Ultimately oral challenge studies in human volunteers would provide the clearest evidence of 
mucosal protection, but measuring antigen specific serum and fecal IgA may provide a correlation with 
protection. B-cells gain the ability to produce IgA after undergoing class switching. Naïve B-cells can be 
stimulated by T-cell dependent antigens or T-cell independent antigens to undergo class switching and 
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produce secretory IgA. Mucosal dendritic cells produce ligands such as APRIL and retinoic acid that 
stimulate class switching in antigen-specific B-cells (Gloudemans 2013). Both B and T cells home to the 
gut via upregulated expression of α4β7 and CCR9. The expression of these receptor is induced by all-
trans retinoic acid production of the antigen presenting cell, whether macrophages or dendritic cells. 
Small blood vessels in the gut constituatively express the ligands for these receptors CXCL13, which 
allows the binding and extravasation of the appropriately marked cells (Mora 2008). The use of Alum as 
an immunoadjuvant has been well documented. Our results demonstrate a predominant effect of Alum 
on the IgG response, specifically anti-OSP IgG, with a decreased IgM response in mice receiving the 
adjuvant. These results are consistent with the previously reported predominance effect of Alum on the 
IgG response. In early studies into the effect of Alum, the main most notable response was seen in the 
IgG production, specifically IgG1 (Fujimaki 1984). Although Alum is FDA approved as a vaccine adjuvant 
in humans, other adjuvants at earlier stages of development may hold promise for both augmenting the 
magnitude of response as well as directing the response towards mucosal immunity. Certain adjuvants 
including retinoic acid and cholera toxin itself have been shown to induce mucosal immune response 
when administered as a component in transcutaneous immunization (Martin 2010). The administration 
of retinoic acid with subcutaneous cholera toxin also produced a protective mucosal response 
(Hammerschmidt 2011). Future work can evaluate combination of the vaccine with other adjuvants such 
as retinoic acid or cholera toxin.  
Antibodies against the OSP moiety limit the growth of V. cholerae in vivo and in vitro which is consistent 
with accessible location of the polysaccharides on the surface of the bacteria. The specificity of the 
OSP:rTTHc vaccine for generating antibodies against OSP as well as the production of a vibriocidal effect 
hold promise as either a primary vaccine or as a boost to be given in conjunction with oral vaccines. The 
antibodies that contribute to the vibriocidal response depend on the epitopes that stimulated the 
response. A high baseline vibriocidal titer correlates, albeit imperfectly, with protection among 
household contact of patients with cholera (Saha 2004). In this experiment, we used the same strain of 
V. cholerae used to produce the vaccine in the vibriocidal assay. The initial outbreak in Haiti was caused 
by an Ogawa serotype organism (Talkington 2011). Isolates of the same genetic strain expressing Inaba 
OSP have been now isolated, however, demonstrating the ability of the bacillus to change serotype (CDC 
2012). Shifts in the predominant serotype of cholera can occur over time as a critical proportion of the 
population develops a protective antibody response (Koelle 2006). Future work can assess cross-
protection against Ogawa, and also assess vaccination with a mixture of Ogawa and Inaba conjugate 
vaccines. Achieving broad protection will likely require the use of multiple strains in the production of a 
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vaccine, although an Inaba based vaccine would give the broadest protection from a monovalent 
immunization. 
This study was limited by the use of a model animal system, which is nonetheless a necessary step prior 
to advancing trials to humans. Although the pathogenicity of V. cholerae is different in mice than 
humans and does not cause disease in adult mice, this study used mouse model to predominantly assess 
immunogenicity of the vaccine. Given the differences between mice and humans, out results would not 
a priori predict the exact response in humans, but are useful in qualitatively comparing the response to 
different vaccine formulations and adjuvants as they are developed.  
Immune correlates of protection facilitate vaccine research, allowing for accelerated screening of 
candidate vaccines prior to large efficacy trials in humans. Although current immune correlates of 
protection for cholera are reliable, further elucidation of the immune responses to target both short and 
long-term immunity will help further efforts to develop a cholera vaccine stimulating lasting immunity.  
In conclusion, cholera is a disease of poverty, persisting in places with limited access to sanitation 
facilities and safe water. The industrial revolution in Britain stimulated a massive urbanization, with poor 
families living in crowded conditions, often in areas with open sewage that emptied into the Thames, 
the main water source for those same people. Although most people living in London in the 19th century 
recognized that poor area such as Soho carried the brunt of the successive cholera pandemics, the 
blame was placed on miasma- “bad air” or simple a moral shortcoming among the poor. John Snow 
famously identified a well on Broad Street as the source of infection for an outbreak. 
John Snow, in publishing a pamphlet on the communication of cholera (Snow 1855), grasped the 
implications that understanding the epidemiology of the disease would have on efforts to control its 
spread: 
“The belief in the communication of cholera is a much less dreary one than the 
reverse; for what is so dismal as the idea of some invisible agent pervading the 
atmosphere, and spreading over the world? IF the writer’s opinions be correct, 
cholera might be checked and kept at bay by simple measures that would not 
interfere with social or commercial intercourse; and the enemy would be shorn of 
his chief terrors. It would only be necessary for all persons attending or waiting on 
the patients to wash their hands carefully and frequently, never omitting to do so 
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before touching food, and for everybody to avoid drinking, or using for culinary 
purposes, water into which drains and sewers empty themselves; or, if that cannot 
be accomplished, to have the water filtered and well boiled before it is used.” 
 Once the waterborne nature of the disease was identified, efforts were made to emphasize clean 
sources of water in addition to general sanitation. Queen Victory and Prince Albert introduced sanitation 
reforms based on massively improved public infrastructure of water and sewage that along with a 
general increase in standard of living removed the threat of cholera epidemics in London. Likewise, 
today cross-disciplinary development focusing on improved standards of living holds the final answer to 
the pathogenic potential of cholera. In the interim, OSP-conjugate vaccines hold promise to limiting the 
burden of cholera among all populations, including children, in endemic areas, as well as providing a 
swifter answer among epidemic stricken populations than that afforded by current oral killed cholera 
vaccines.  
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Figure 1. ELISA response in mice vaccinated with and without adjuvant.  
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Figure 2. Vibriocidal titer. Both the conjugate vaccine alone and when combined with Alum produced a statistically significant 
response over baseline.  
18 
 
LD-50 Survival Curve
0 6 12 18 24 30 36
0
20
40
60
80
100
Inaba OSPc:rTThc
    + Alum (n=17)
Alum only (n=13)
p=0.0006
hours
P
e
rc
e
n
t 
s
u
rv
iv
a
l
 
Figure 3. Protection assay in infant mice. Of the mice pups treated with serum from vaccinated mice, 10/17 (58.8%) survived to 
36 hours compared with 1/13 (7.7%)( p=.0006) of mice who received serum from mice vaccinated with Alum alone. 
 
